Introduction {#sec1}
============

Besides homonuclear N-heterocyclic compounds, many synthetic methods for their N-fused hybrid scaffolds have been attempted and developed because of characteristic biological activities that are not shown in each homonuclear scaffolds. It is known that homonuclear pyrimidine- and benzimidazolequinone (1*H*-benzo\[*d*\]imidazole-4,7-dione)-containing compounds show diverse biological activities, such as anticancer, antimalarial, antitumor, antiproliferative, and cytotoxic properties.^[@ref1],[@ref2]^ There are two N-fused modes of such homonuclear N-heterocycles, benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidine-6,9-diones ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, **A**) and benzo\[4,5\]imidazo\[1,2-*c*\]pyrimidine-6,9-diones ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}, **B**). In contrast to many synthetic methods for other N-fused hybrid scaffolds, limited examples for the synthesis of such N-fused hybrid scaffolds **A** and **B** are known. It is reported that N-fused hybrid scaffold **A** can be synthesized by the reaction of 2-aminopyrimidine with *p*-chloranil (2,3,5,6-tetrachloro-1,4-benzoquinone) followed by subsequent treatment with diethylamine and HCl ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}).^[@ref3]^ We reported on the synthesis of N-fused hybrid scaffold **B** by step-by-step copper-catalyzed coupling and cyclization of 2-(2-bromovinyl)-4,7-dimethoxybenzimidazoles with primary amides to form pyrimidine-fused 4,7-dimethoxybenzimidazoles, and oxidation of such intermediates by aqueous ceric ammonium nitrate (CAN) ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}).^[@ref4]^ As part of our continuing studies directed toward transition metal--catalyzed and transition metal--free cyclization reactions for heterocycles,^[@ref5]^ we have shown several new synthetic protocols for N-fused hybrid scaffolds.^[@ref6]^ Among them, β-bromo-α,β-unsaturated aldehydes were found to be cyclocondensed with 2-aminobenzimidazole in the presence of a base under microwave irradiation to give pyrimidine-fused benzimidazoles, benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidines.^[@ref7],[@ref8]^ Under these circumstances, the present work started during the course of a combinatorial extension of such protocols to develop a new synthetic approach for N-fused hybrid scaffolds. Herein we provide another example for the synthetic method of N-fused hybrid scaffold **A** by sequential cyclocondensation between β-bromo-α,β-unsaturated aldehydes and 2-aminobenzimidazole analogue, 4,7-dimethoxy-1*H*-benzo\[*d*\]imidazole-2-amine and oxidation ([Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}).

![Two N-Fused Modes of Benzimidazolequinone and Pyrimidine](ao-2018-02755g_0001){#sch1}

![Synthesis of Benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidine-6,9-diones **A** and Benzo\[4,5\]imidazo\[1,2-*c*\]pyrimidine-6,9-diones **B**](ao-2018-02755g_0002){#sch2}

Results and Discussion {#sec2}
======================

First, we optimized the reaction conditions to produce precursors, dimethoxy-substituted benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidines of N-fused hybrid scaffold **A** effectively. On the basis of recent reports on transition metal--free cyclocondensation of β-bromo-α,β-unsaturated aldehydes and 2-halobenzaldehydes with 2-aminobenzimidazole,^[@ref7],[@ref9]^[Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"} shows several attempted results for the cyclocondensation of 2-bromocyclohex-1-enecarbaldehyde (**1a**) with 4,7-dimethoxy-1*H*-benzo\[*d*\]imidazole-2-amine (**2a**) under various reaction conditions, leading to 8,11-dimethoxy-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*a*\]quinazoline (**3a**). The starting **2a** was prepared from 3,6-dimethoxybenzene-1,2-diamine^[@cit2b],[@ref10]^ and cyanogen bromide using similar methods reported.^[@ref11]^ Treatment of **1a** with equimolar amount of **2a** in dimethylformamide (DMF) at 110 °C for 1 h in the presence of K~2~CO~3~ under microwave irradiation afforded **3a** in 64% isolated yield ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 1). The molar ratio of **2a** to **1a**, although not significant, affected the yield of **3a**, and the yield increased with the increase in the molar ratio up to 1.2 without other identifiable by-products ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 1--3). Lower yield of **3a** was observed under lower reaction temperature, and the yield increased with the increase in temperature up to 110 °C ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 2, 4, and 5). Prolonging the reaction time up to 1 h was needed for the effective formation of **3a** with complete conversion of **1a** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 2, 6, and 7). In contrast to the reaction between β-bromo-α,β-unsaturated aldehydes and 2-aminobenzimidazoles,^[@ref7]^ further addition of magnesium sulfate resulted in rather decreased yield of **3a** ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 8). The reaction also proceeded in the presence of other inorganic bases such as K~3~PO~4~, NaO^*t*^Bu, NaOAc, Cs~2~CO~3~, and CsF, but the yields of **3a** were generally lower than that obtained in the presence of K~2~CO~3~ ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 9--13).^[@ref12]^ Unlike the previous cyclocondensation of β-bromo-α,β-unsaturated aldehydes and 2-aminobenzimidazoles, no allowable yield of **3a** was observed with Et~3~N ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 14). When **1a** was treated with **2a** under usual heating conditions (screw-capped vial) for 10 h, **3a** was obtained in 52% yield ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 15).

###### Optimization of Conditions for the Reaction of **1a** with **2a**[a](#t1fn1){ref-type="table-fn"}

![](ao-2018-02755g_0004){#GRAPHIC-d7e441-autogenerated}

  entry                                \[**1a**\]/\[**2a**\]   base         temp. (°C)   time (h)   yield (%)
  ------------------------------------ ----------------------- ------------ ------------ ---------- -----------
  1                                    1/1                     K~2~CO~3~    110          1          64
  2                                    1/1.2                   K~2~CO~3~    110          1          68
  3                                    1/1.5                   K~2~CO~3~    110          1          69
  4                                    1/1.2                   K~2~CO~3~    85           1          43
  5                                    1/1.2                   K~2~CO~3~    135          1          68
  6                                    1/1.2                   K~2~CO~3~    110          0.5        51
  7                                    1/1.2                   K~2~CO~3~    110          2          70
  8[b](#t1fn2){ref-type="table-fn"}    1/1.2                   K~2~CO~3~    110          1          57
  9                                    1/1.2                   K~3~PO~4~    110          1          54
  10                                   1/1.2                   NaO^*t*^Bu   110          1          26
  11                                   1/1.2                   NaOAc        110          1          40
  12                                   1/1.2                   Cs~2~CO~3~   110          1          39
  13                                   1/1.2                   CsF          110          1          45
  14                                   1/1.2                   Et~3~N       110          1          28
  15[c](#t1fn3){ref-type="table-fn"}   1/1.2                   K~2~CO~3~    110          10         52

**1a** (0.3 mmol), base (0.9 mmol), additive (0.6 mmol), microwave irradiation (100 W initial power), DMF (3 mL), unless otherwise stated.

Further addition of MgSO~4~ (0.6 mmol).

Under usual heating (screw-capped vial).

Having optimized the reaction conditions, various β-bromo-α,β-unsaturated aldehydes **1** were subjected to the reaction with **2a** to investigate the reaction scope, and several representative results are summarized in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}. The cyclocondensation of 2-bromocyclohex-1-enecarbaldehydes (**1b** and **1c**) with **2a** also proceeded to give the corresponding pyrimidine-fused benzimidazoles (**3b** and **3c**) in similar yields, irrespective of the presence of the methyl and phenyl substituents on **1b** and **1c**. With cyclic β-bromo-α,β-unsaturated aldehydes **1d--f** having various ring sizes, the corresponding N-fused scaffolds **3d--f** were also formed in 72--82% yields. The reaction of benzo-fused β-bromo-α,β-unsaturated aldehydes **1g** took place with **2a** to give 8,11-dimethoxy-13,14-dihydrobenzo\[*f*\]benzo\[4,5\]imidazo\[1,2-*a*\]quinazoline (**3g**) in 21% yield along with its dehydrogenated product **3g′** (35% yield). Performing the reaction for prolonging reaction time (2 h) under the employed conditions solely afforded **3g′** in 61% yield. This result indicates that **3g′** is produced by dehydrogenation of **3g** initially formed by the cyclization of **1g**. Such a similar dehydrogenation was observed by our recent reports on coupling and cyclizaton reactions using similar benzo-fused six-membered ring substrates.^[@cit5c],[@cit5d],[@cit6b],[@cit6c]^ Acyclic β-bromo-α,β-unsaturated aldehydes **1h--o** having alkyl and aryl substituents were also cyclocondensed with **2a** to afford pyrimidine-fused benzimidazoles **3h--o** in 55--67% yields and the product yield was not significantly affected by the identity of such substituents.

###### Cyclocondensation of **1** with **2a** Leading to **3**[a](#t2fn1){ref-type="table-fn"}

![](ao-2018-02755g_0005){#GRAPHIC-d7e970-autogenerated}
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Reaction conditions: **1** (0.3 mmol), **2** (0.36 mmol), K~2~CO~3~ (0.9 mmol), DMF (3 mL), 110 °C, 1 h, under microwave irradiation (100 W of initial power).

Similar treatment of 2-bromobenzaldehydes (**1p** and **1q**) with **2a** under the employed conditions produced the corresponding quinazoline-fused benzimidazoles (**3p** and **3q**) in 71 and 50% yields, respectively. Benzo-fused analogue **1r** also reacted with **2a** to give such a hybrid scaffold **3r** in 63% yield. In contrast to many synthetic methods for pyrimidine-fused benzimidazoles,^[@ref8]^ benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidines, limited examples are known for the construction of quinazoline-fused benzimidazoles, benzo\[4,5\]imidazo\[1,2-*a*\]quinazolines.^[@ref9],[@ref13],[@ref14]^ Wang and Singh reported that *N*-(2-benzimidazoyl)-2-aminobenzamides react with 2-bromobenzaldehydes in the presence or absence of CuI and [l]{.smallcaps}-proline to afford benzo\[4,5\]imidazo\[1,2-*a*\]quinazolines via Ullmann-type C--N coupling followed by double C--N bond cleavage.^[@ref13]^ Such a similar C--N coupling for eventual formation of benzo\[4,5\]imidazo\[1,2-*a*\]quinazoline was also exemplified by copper-catalyzed reaction between 2-bromobenzoic acid and 2-aminobenzimidazole.^[@ref14]^ However, to the best of our knowledge, no reports are found for the biological activities of such scaffolds.

As to the reaction pathway, although it is not certain, this seems to proceed via an initial formation of Schiff base by condensation between **1** and **2a**. This is followed by intramolecular nucleophilic aromatic substitution under basic conditions to give **3**.^[@ref9]^ A reviewer commented on how **1** will behave in reactions with unsymmetrically substituted 2-aminobenzimidazoles having electron-donating and electron-withdrawing groups. The reaction of 2-bromobenzaldehyde (**1p**) with unsymmetrically substituted 2-aminobenzimidazoles (**2b** and **2c**) under the employed conditions afforded the corresponding cyclocondensation products (**3s** and **3t**) as isomeric mixtures in 30 and 19% yields, respectively ([Scheme [3](#sch3){ref-type="scheme"}](#sch3){ref-type="scheme"}, see [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.8b02755/suppl_file/ao8b02755_si_001.pdf) for ^1^H NMR spectra).^[@cit11a]^

![Reactions with Unsymmetrically Substituted 2-Aminobenzimidazoles](ao-2018-02755g_0003){#sch3}

Oxidation of all pyrimidine- and quinazoline-fused dimethoxybenzimidazoles **3a--r** shown in [Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"} except for **3g** by treatment of CAN in aqueous acetonitrile afforded benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidine-6,9-diones and benzo\[4,5\]imidazo\[1,2-*a*\]quinazoline-8,11-diones, respectively, in high yields ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}).^[@cit2b],[@cit2j],[@ref15]^ Not fully understood, **3g′** was readily oxidized to the corresponding benzimidazolequinone **4g** in similar yield, whereas no expected oxidation product was observed with **3g**. No reports for benzo\[4,5\]imidazo\[1,2-*a*\]quinazoline-8,11-diones are known for synthetic methods and biological activities.

###### Oxidation of **3--4** with CAN[a](#t3fn1){ref-type="table-fn"}

![](ao-2018-02755g_0007){#GRAPHIC-d7e1153-autogenerated}

![](ao-2018-02755g_0008){#gr5}

Reaction conditions: **3** (0.1 mmol), CAN (0.3 mmol), acetonitrile/H~2~O (4 mL), 0 °C, 20 min.

Conclusions {#sec3}
===========

In summary, we have shown that β-bromo-α,β-unsaturated aldehydes and 2-bromobenzaldehydes trigger cyclocondensation with 4,7-dimethoxy-1*H*-benzo\[*d*\]imidazole-2-amine under microwave irradiation in the presence of a base to form the corresponding dimethoxy-substituted benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidines and benzo\[4,5\]imidazo\[1,2-*a*\]quinazolines, respectively. Such scaffolds could be oxidized into benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidine-6,9-diones and benzo\[4,5\]imidazo\[1,2-*a*\]quinazoline-8,11-diones by treatment with aqueous CAN. The present reaction would be served as a useful method for designing and synthesizing bioreductive quinone-based drugs. Further studies on the synthesis of unprecedented benzimidazole-based 1,4-quinone-containing N-fused hybrid scaffolds using the present protocol are expected.

Experimental Section {#sec4}
====================

General Information {#sec4.1}
-------------------

^1^H and ^13^C NMR spectra were obtained at 500 and 125 MHz, respectively, in DMSO-*d*~6~ or CDCl~3~. Melting points were measured on a microscopic melting point apparatus. High-resolution mass data were recorded using electronic ionization (HRMS-EI, magnetic sector--electric sector double focusing mass analyzer) at the Korea Basic Science Center (Daegu). All microwave reactions (CEM, Discover LabMate) were performed in a 5 mL tube, and maintenance of the reaction temperature was monitored by an external infrared sensor. The crude reaction mixtures were purified by thin-layer (a glass plate coated with Kieselgel 60 GF~254~, Merck) chromatography. The starting aldehydes were prepared from the corresponding ketones according to literature procedures.^[@ref16]^ 4,7-Dimethoxy-1*H*-benzo\[*d*\]imidazole-2-amine (**2a**) was prepared from 3,6-dimethoxybenzene-1,2-diamine and cyanogen bromide using the procedure shown below.^[@ref17]^ 3,6-Dimethoxybenzene-1,2-diamine was synthesized by a known method from hydroquinone via a three-step sequence (methylation, nitration, reduction).^[@cit2b],[@ref10]^ All other commercially available chemicals were used without further purification.

Synthesis of 4,7-Dimethoxy-1*H*-benzo\[*d*\]imidazole-2-amine (**2a**) {#sec4.2}
----------------------------------------------------------------------

To a solution of 3,6-dimethoxybenzene-1,2-diamine (1.682 g, 10 mmol) in MeOH/H~2~O (100 mL, 1:1), cyanogen bromide (3.178 g, 30 mmol) was added. The reaction mixture was stirred at 50 °C for 3 h. After the mixture was cooled to room temperature, neutralized with 10% aqueous NaOH solution (to pH = 10), and extracted with EtOAc (50 mL, 3 times), the combined organic layer was dried over Na~2~SO~4~. Removal of the solvent left a crude mixture, which was purified by a short silica gel column (dichloromethane/MeOH = 7:3) to yield a pale yellow solid **2a** (1.777 g, 92%). ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 3.85 (s, 6H), 6.75 (s, 2H), 7.75 (s, 2H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 56.01, 104.6, 122.1, 140.0, 151.3. HRMS (EI): calcd for C~9~H~11~N~3~O~2~ (M^+^), 193.0851; found, 193.0849.

General Procedure for the Synthesis of **3** {#sec4.3}
--------------------------------------------

To a 5 mL microwave reaction tube, **1** (0.3 mmol), **2a** (0.070 g, 0.36 mmol), K~2~CO~3~ (0.124 g, 0.9 mmol), and DMF (3 mL) were added. After stirring at room temperature for 5 min, the reaction mixture was heated at 110 °C for 1 h by microwave irradiation (100 W initial power). The mixture was cooled to room temperature and filtered through a short silica gel column (ethyl acetate) to eliminate inorganic components. Evaporation of the solvent under reduced pressure gave a crude mixture, which was purified by TLC (dichloromethane/methanol = 97/3) to give **3**. Spectroscopic data for all products are shown below.

### 8,11-Dimethoxy-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*a*\]quinazoline (**3a**) {#sec4.3.1}

*R*~f~ = 0.34. Pale yellow solid (58 mg, 68%). mp 192--195 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 1.86--1.90 (m, 2H), 1.93--1.98 (m, 2H), 2.85--2.87 (m, 2H), 3.04--3.07 (m, 2H), 4.02 (s, 3H), 4.07 (s, 3H), 6.61 (d, *J* = 8.6 Hz, 1H), 6.79 (d, *J* = 8.6 Hz, 1H), 8.90 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 22.5, 22.6, 26.3, 33.8, 55.9, 56.9, 100.9, 106.3, 116.9, 117.5, 133.7, 136.8, 143.5, 145.6, 149.5, 165.9. HRMS (EI): calcd for C~16~H~17~N~3~O~2~ (M^+^), 283.1321; found, 283.1318.

### 8,11-Dimethoxy-3-methyl-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*a*\]quinazoline (**3b**) {#sec4.3.2}

*R*~f~ = 0.35. Pale yellow solid (50 mg, 56%). mp 179--181 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 1.14 (d, *J* = 6.6 Hz, 3H), 1.54--1.62 (m, 1H), 1.93--2.01 (m, 1H), 2.02--2.07 (m, 1H), 2.45--2.50 (m, 1H), 2.92--2.96 (m, 1H), 2.99--3.06 (m, 1H), 3.15--3.21 (m, 1H), 4.03 (s, 3H), 4.07 (s, 3H), 6.62 (d, *J* = 8.6 Hz, 1H), 6.80 (d, *J* = 8.6 Hz, 1H), 8.91 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 21.5, 28.9, 30.6, 33.2, 34.6, 55.8, 56.9, 100.8, 106.2, 116.4, 117.4, 133.5, 136.8, 143.4, 145.6, 149.5, 165.6. HRMS (EI): calcd for C~17~H~19~N~3~O~2~ (M^+^), 297.1477; found, 297.1474.

### 8,11-Dimethoxy-3-phenyl-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*a*\]quinazoline (**3c**) {#sec4.3.3}

*R*~f~ = 0.32. Pale yellow solid (69 mg, 64%). mp 197--199 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 2.10--2.16 (m, 1H), 2.28--2.32 (m, 1H), 2.96--3.02 (m, 1H), 3.06--3.20 (m, 3H), 3.27--3.32 (m, 1H), 4.01 (s, 3H), 4.07 (s, 3H), 6.63 (d, *J* = 8.6 Hz, 1H), 6.81 (d, *J* = 8.6 Hz, 1H), 7.26--7.27 (m, 1H), 7.29--7.31 (m, 2H), 7.35--7.38 (m, 2H). ^13^C NMR (125 MHz, CDCl~3~): δ 29.7, 33.7, 34.2, 40.1, 55.8, 56.9, 100.9, 106.3, 116.3, 117.4, 126.7, 126.8, 128.7, 133.7, 136.8, 143.4, 144.9, 145.6, 149.5, 165.0. HRMS (EI): calcd for C~22~H~21~N~3~O~2~ (M^+^), 359.1634; found, 359.1632.

### 9,12-Dimethoxy-2,3,4,5-tetrahydro-1*H*-benzo\[4,5\]imidazo\[1,2-*a*\]cyclohepta\[*e*\]pyrimidine (**3d**) {#sec4.3.4}

*R*~f~ = 0.36. Pale yellow solid (64 mg, 72%). mp 225--226 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 1.74--1.78 (m, 2H), 1.89--1.93 (m, 2H), 1.94--1.99 (m, 2H), 2.87--2.89 (m, 2H), 3.56--3.58 (m, 2H), 3.95 (s, 3H), 4.04 (s, 3H), 6.64 (d, *J* = 8.6 Hz, 1H), 6.84 (d, *J* = 8.6 Hz, 1H), 8.47 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 25.1, 27.3, 30.7, 32.0, 34.0, 56.3, 56.4, 102.0, 105.8, 118.8, 122.6, 138.4, 142.3, 145.8, 151.5, 154.0, 156.1. HRMS (EI): calcd for C~17~H~19~N~3~O~2~ (M^+^), 297.1477; found, 297.1474.

### 10,13-Dimethoxy-1,2,3,4,5,6-hexahydrobenzo\[4,5\]imidazo\[1,2-*a*\]cycloocta\[*e*\]pyrimidine (**3e**) {#sec4.3.5}

*R*~f~ = 0.42. Pale yellow solid (77 mg, 82%). mp 186--187 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 1.34--1.38 (m, 2H), 1.44--1.49 (m, 2H), 1.72--1.77 (m, 2H), 1.88--1.93 (m, 2H), 2.80--2.82 (m, 2H), 3.65--3.68 (m, 2H), 6.65 (d, *J* = 8.6 Hz, 1H), 6.82 (d, *J* = 8.6 Hz, 1H), 8.45 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 25.7, 26.1, 29.0, 29.4, 29.6, 31.7, 55.9, 56.3, 102.2, 105.3, 118.8, 119.8, 138.0, 141.5, 145.8, 150.7, 151.3, 156.5. HRMS (EI): calcd for C~18~H~21~N~3~O~2~ (M^+^), 311.1634; found, 311.1632.

### 14,17-Dimethoxy-1,2,3,4,5,6,7,8,9,10-decahydrobenzo\[4,5\]imidazo\[1,2-*a*\]cyclododeca\[*e*\]pyrimidine (**3f**) {#sec4.3.6}

*R*~f~ = 0.47. Pale yellow solid (83 mg, 75%). mp 195--198 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 1.39--1.46 (m, 8H), 1.50--1.60 (m, 4H), 1.63--1.68 (m, 2H), 1.77--1.83 (m, 2H), 2.78--2.81 (m, 2H), 3.64--3.68 (m, 2H), 6.71 (d, *J* = 8.6 Hz, 1H), 6.86 (d, *J* = 8.6 Hz, 1H), 8.57 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 21.9, 22.8, 24.6, 24.7, 25.5, 25.9, 26.5, 27.0, 28.2, 29.7, 56.0, 56.4, 102.3, 105.4, 119.3, 119.5, 138.1, 141.9, 146.0, 151.1, 151.3, 157.6. HRMS (EI): calcd for C~22~H~29~N~3~O~2~ (M^+^), 367.2260; found, 367.2258.

### 8,11-Dimethoxy-13,14-dihydrobenzo\[*f*\]benzo\[4,5\]imidazo\[1,2-*a*\]quinazoline (**3g**) {#sec4.3.7}

*R*~f~ = 0.39. Pale yellow solid (21 mg, 21%). mp 171--174 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 3.06--3.09 (m, 2H), 3.21--3.24 (m, 2H), 4.07 (s, 3H), 4.09 (s, 3H), 6.68 (d, *J* = 8.6 Hz, 1H), 6.82 (d, *J* = 8.6 Hz, 1H), 7.31--7.32 (m, 2H), 7.35--7.40 (m, 1H), 7.71 (d, *J* = 7.6 Hz, 1H), 9.45 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 28.2, 33.2, 56.0, 56.8, 101.6, 106.5, 116.0, 118.0, 122.8, 127.5, 128.4, 128.7, 129.7, 130.2, 136.5, 136.6, 143.4, 145.7, 149.1, 165.7. HRMS (EI): calcd for C~20~H~17~N~3~O~2~ (M^+^), 331.1321; found, 331.1320.

### 8,11-Dimethoxy\[*f*\]benzo\[4,5\]imidazo\[1,2-*a*\]quinazoline (**3g′**) {#sec4.3.8}

*R*~f~ = 0.37. Pale yellow solid (35 mg, 35%). mp 194--196 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 3.87 (s, 3H), 3.92 (s, 3H), 6.61 (d, *J* = 8.6 Hz, 1H), 6.66 (d, *J* = 8.6 Hz, 1H), 7.34--7.37 (m, 1H), 7.45--7.48 (m, 1H), 7.67 (d, *J* = 7.9 Hz, 1H), 7.88 (d, *J* = 9.4 Hz, 1H), 8.32 (d, *J* = 8.4 Hz, 1H), 9.03 (d, *J* = 9.4 Hz, 1H), 9.65 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 56.5, 57.1, 105.0, 105.5, 113.0, 119.3, 120.6, 121.5, 126.7, 128.9, 129.1, 129.4, 130.0, 134.8, 137.3, 138.2, 141.3, 146.7, 150.1, 152.8. HRMS (EI): calcd for C~20~H~15~N~3~O~2~ (M^+^), 329.1164; found, 329.1161.

### 6,9-Dimethoxy-4-phenylbenzo\[4,5\]imidazo\[1,2-*a*\]pyrimidine (**3h**) {#sec4.3.9}

*R*~f~ = 0.27. Pale yellow solid (57 mg, 62%). mp 68--71 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 3.11 (s, 3H), 4.06 (s, 3H), 6.45 (d, *J* = 8.6 Hz, 1H), 6.75 (d, *J* = 4.2 Hz, 1H), 6.84 (d, *J* = 8.6 Hz, 1H), 7.43--7.55 (m, 5H), 8.75 (d, *J* = 4.2 Hz, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 55.3, 56.6, 102.1, 106.3, 109.2, 118.6, 126.9, 128.0, 129.7, 136.9, 137.8, 142.3, 145.5, 150.9, 151.7, 154.2. HRMS (EI): calcd for C~18~H~15~N~3~O~2~ (M^+^), 305.1164; found, 305.1166.

### 6,9-Dimethoxy-3-methyl-4-phenylbenzo\[4,5\]imidazo\[1,2-*a*\]pyrimidine (**3i**) {#sec4.3.10}

*R*~f~ = 0.38. Pale yellow solid (58 mg, 61%). mp 215--218 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 2.13 (s, 3H), 3.06 (s, 3H), 4.04 (s, 3H), 6.36 (d, *J* = 8.6 Hz, 1H), 6.78 (d, *J* = 8.6 Hz, 1H), 7.31--7.32 (m, 2H), 7.51--7.53 (m, 3H), 8.67 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 15.9, 55.6, 56.4, 101.7, 105.7, 115.5, 118.6, 128.2, 128.3, 129.2, 135.6, 137.8, 142.1, 145.4, 147.2, 151.0, 157.4. HRMS (EI): calcd for C~19~H~17~N~3~O~2~ (M^+^), 319.1321; found, 319.1319.

### 3-Butyl-6,9-dimethoxy-4-phenylbenzo\[4,5\]imidazo\[1,2-*a*\]pyrimidine (**3j**) {#sec4.3.11}

*R*~f~ = 0.39. Pale yellow solid (73 mg, 67%). mp 148--151 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 0.79 (t, *J* = 7.4 Hz, 3H), 1.19--1.26 (m, 2H), 1.42--1.48 (m, 2H), 2.42--2.45 (m, 2H), 3.06 (s, 3H), 4.04 (s, 3H), 6.36 (d, *J* = 8.6 Hz, 1H), 6.77 (d, *J* = 8.6 Hz, 1H), 7.32--7.35 (m, 2H), 7.48--7.53 (m, 3H), 8.69 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 13.6, 22.3, 28.9, 33.4, 55.7, 56.4, 101.7, 105.6, 118.8, 120.4, 128.0, 128.5, 129.2, 135.0, 137.8, 142.1, 145.4, 147.0, 150.8, 157.3. HRMS (EI): calcd for C~22~H~23~N~3~O~2~ (M^+^), 361.1790; found, 361.1788.

### 3-Isopropyl-6,9-dimethoxy-4-phenylbenzo\[4,5\]imidazo\[1,2-*a*\]pyrimidine (**3k**) {#sec4.3.12}

*R*~f~ = 0.34. Pale yellow solid (65 mg, 62%). mp 152--157 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 1.22 (d, *J* = 7.0 Hz, 6H), 2.75--2.84 (m, 1H), 3.06 (s, 3H), 4.04 (s, 3H), 6.35 (d, *J* = 8.6 Hz, 1H), 6.77 (d, *J* = 8.6 Hz, 1H), 7.32--7.34 (m, 2H), 7.51--7.53 (m, 3H), 8.83 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 23.4, 27.5, 55.8, 56.5, 101.7, 105.6, 118.9, 125.4, 128.1, 128.6, 129.2, 134.9, 138.0, 142.1, 145.5, 146.0, 150.6, 154.8. HRMS (EI): calcd for C~21~H~21~N~3~O~2~ (M^+^), 347.1634; found, 347.1632.

### 6,9-Dimethoxy-3,4-diphenylbenzo\[4,5\]imidazo\[1,2-*a*\]pyrimidine (**3l**) {#sec4.3.13}

*R*~f~ = 0.41. Pale yellow solid (66 mg, 58%). mp 222--223 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 4.02 (s, 3H), 4.09 (s, 3H), 6.68 (d, *J* = 8.6 Hz, 1H), 6.86 (d, *J* = 8.6 Hz, 1H), 7.24--7.28 (m, 4H), 7.31--7.37 (m, 4H), 7.51--7.53 (m, 2H), 9.19 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 55.9, 56.9, 101.6, 106.8, 117.7, 121.3, 127.83, 127.84, 128.7, 129.5, 129.9, 130.2, 136.0, 136.5, 137.4, 137.9, 143.5, 145.7, 149.2, 162.3. HRMS (EI): calcd for C~24~H~19~N~3~O~2~ (M^+^), 381.1477; found, 381.1474.

### 4-Ethyl-6,9-dimethoxy-3-methylbenzo\[4,5\]imidazo\[1,2-*a*\]pyrimidine (**3m**) {#sec4.3.14}

*R*~f~ = 0.42. Pale yellow solid (45 mg, 55%). mp 133--135 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 1.41 (t, *J* = 7.4 Hz, 3H), 2.34 (d, *J* = 1.1 Hz, 3H), 2.90 (q, *J* = 7.4 Hz, 2H), 4.03 (s, 3H), 4.08 (s, 3H), 6.62 (d, *J* = 8.6 Hz, 1H), 6.80 (d, *J* = 8.6 Hz, 1H), 8.89 (q, *J* = 1.1 Hz, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 11.0, 15.8, 29.4, 55.8, 57.1, 100.9, 106.4, 115.3, 117.5, 133.3, 136.6, 143.3, 145.7, 149.8, 169.0. HRMS (EI): calcd for C~15~H~17~N~3~O~2~ (M^+^), 271.1321; found, 271.1318.

### 6,9-Dimethoxy-4-(naphthalen-2-yl)benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidine (**3n**) {#sec4.3.15}

*R*~f~ = 0.38. Pale yellow solid (65 mg, 61%). mp 154--157 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 2.77 (s, 3H), 4.07 (s, 3H), 6.40 (d, *J* = 8.6 Hz, 1H), 6.84 (d, *J* = 8.6 Hz, 1H), 6.86 (d, *J* = 3.9 Hz, 1H), 7.49 (dd, *J* = 8.5 and 1.6 Hz, 1H), 7.56--7.62 (m, 2H), 7.90--7.94 (m, 3H), 8.03 (s, 1H), 8.79 (d, *J* = 3.9 Hz, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 54.9, 56.5, 102.2, 106.3, 109.5, 118.7, 124.5, 126.3, 126.9, 127.28, 127.32, 127.8, 128.4, 132.7, 133.7, 134.3, 137.9, 142.2, 145.6, 150.9, 151.7, 154.2. HRMS (EI): calcd for C~22~H~17~N~3~O~2~ (M^+^), 355.1321; found, 355.1318.

### 4-(Furan-3-yl)-6,9-dimethoxybenzo\[4,5\]imidazo\[1,2-*a*\]pyrimidine (**3o**) {#sec4.3.16}

*R*~f~ = 0.36. Pale yellow solid (50 mg, 57%). mp 127--128 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 4.05 (s, 3H), 4.10 (s, 3H), 6.63 (dd, *J* = 3.5 and 1.7 Hz, 1H), 6.67 (d, *J* = 8.6 Hz, 1H), 6.85 (d, *J* = 8.6 Hz, 1H), 7.32 (d, *J* = 7.2 Hz, 1H), 7.49 (dd, *J* = 3.5 and 0.5 Hz, 1H), 7.64--7.65 (m, 1H), 9.22 (d, *J* = 7.2 Hz, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 55.9, 57.2, 101.6, 102.7, 107.1, 111.8, 113.1, 113.5, 118.0, 136.5, 143.3, 144.1, 145.3, 145.6, 152.2, 152.3. HRMS (EI): calcd for C~16~H~13~N~3~O~3~ (M^+^), 295.0957; found, 295.0954.

### 8,11-Dimethoxybenzo\[4,5\]imidazo\[1,2-*a*\]quinazoline (**3p**) {#sec4.3.17}

*R*~f~ = 0.37. Pale yellow solid (59 mg, 71%). mp 210--214 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 4.06 (s, 3H), 4.07 (s, 3H), 6.89 (s, 2H), 7.52--7.55 (m, 1H), 7.86--7.90 (m, 1H), 7.95 (dd, *J* = 7.8 and 1.5 Hz, 1H), 9.11 (s, 1H), 9.38 (d, *J* = 8.7 Hz, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 56.5, 57.1, 105.2, 105.6, 119.1, 120.3, 121.1, 124.8, 129.2, 133.9, 136.6, 138.0, 141.1, 146.8, 150.0, 158.4. HRMS (EI): calcd for C~16~H~13~N~3~O~2~ (M^+^), 279.1008; found, 279.1009.

### 3-Fluoro-8,11-dimethoxybenzo\[4,5\]imidazo\[1,2-*a*\]quinazoline (**3q**) {#sec4.3.18}

*R*~f~ = 0.53. Pale yellow solid (45 mg, 50%). mp 214--217 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 4.06 (s, 3H), 4.07 (s, 3H), 6.89 (d, *J* = 8.8 Hz, 1H), 6.91 (d, *J* = 8.8 Hz, 1H), 7.61--7.64 (m, 2H), 9.07 (s, 1H), 9.44--9.47 (m, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 56.3, 57.0, 105.1, 105.5, 113.7 (d, ^2^*J*~C--F~ = 22.0 Hz, 1C), 119.8 (d, ^3^*J*~C--F~ = 7.5 Hz, 1C), 120.9, 121.7 (d, ^2^*J*~C--F~ = 23.3 Hz, 1C), 122.6 (d, ^3^*J*~C--F~ = 7.3 Hz, 1C), 134.5, 136.5, 140.8, 146.8, 149.6, 157.0 (d, ^4^*J*~C--F~ = 3.0 Hz, 1C), 158.9 (d, ^1^*J*~C--F~ = 246.0 Hz, 1C). HRMS (EI): calcd for C~16~H~12~FN~3~O~2~ (M^+^), 297.0914; found, 297.0912.

### 10,13-Dimethoxybenzo\[*h*\]benzo\[4,5\]imidazo\[1,2-*a*\]quinazoline (**3r**) {#sec4.3.19}

*R*~f~ = 0.39. Pale yellow solid (62 mg, 63%). mp 223--225 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 3.51 (s, 3H), 4.14 (s, 3H), 6.74 (d, *J* = 8.6 Hz, 1H), 6.94 (d, *J* = 8.6 Hz, 1H), 7.45 (dd, *J* = 7.5 and 7.4 Hz, 1H), 7.72 (dd, *J* = 7.5 and 7.5 Hz, 1H), 7.86 (d, *J* = 8.5 Hz, 1H), 7.92 (d, *J* = 8.5 Hz, 1H), 7.96--7.97 (m, 1H), 8.45--8.47 (m, 1H), 9.17 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 54.7, 56.7, 103.1, 105.8, 116.8, 122.7, 123.1, 123.4, 124.8, 125.2, 126.3, 127.1, 129.6, 135.4, 137.1, 137.6, 143.3, 146.2, 151.6, 156.7. HRMS (EI): calcd for C~20~H~15~N~3~O~2~ (M^+^), 329.1164; found, 329.1162.

General Procedure for the Oxidation of **3--4** {#sec4.4}
-----------------------------------------------

A solution of CAN (0.165 g, 0.3 mmol) in acetonitrile/H~2~O (9:1, 2 mL) was added dropwise to a stirred solution of **3** (0.1 mmol) in acetonitrile/H~2~O (7:3, 2 mL) in an ice bath. After stirring for 20 min in the ice bath, the reaction mixture was poured into cold water and then extracted with ethyl acetate (20 mL, 3 times). Evaporation of the combined solvent under reduced pressure and recrystallization from dichloromethane and hexane mixture gave **4**.

### 1,2,3,4-Tetrahydrobenzo\[4,5\]imidazo\[1,2-*a*\]quinazoline-8,11-dione (**4a**) {#sec4.4.1}

*R*~f~ = 0.47. Brown solid (22 mg, 85%). mp 236--238 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.79--1.82 (m, 2H), 1.87--1.92 (m, 2H), 2.90--2.92 (m, 2H), 2.98--3.00 (m, 2H), 6.81 (d, *J* = 10.4 Hz, 1H), 6.87 (d, *J* = 10.4 Hz, 1H), 9.13 (s, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 21.4, 21.6, 25.3, 33.0, 120.7, 123.8, 132.9, 136.4, 137.4, 144.0, 149.3, 166.9, 176.4, 182.2. HRMS (EI): calcd for C~14~H~11~N~3~O~2~ (M^+^), 253.0851; found, 253.0854.

### 3-Methyl-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*a*\]quinazoline-8,11-dione (**4b**) {#sec4.4.2}

*R*~f~ = 0.54. Brown solid (21 mg, 80%). mp 219--221 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.06 (d, *J* = 6.6 Hz, 3H), 1.46--1.54 (m, 1H), 1.88--1.99 (m, 2H), 2.36--2.42 (m, 1H), 2.83--2.88 (m, 1H), 2.91--2.98 (m, 1H), 3.07--3.13 (m, 1H), 6.81 (d, *J* = 10.4 Hz, 1H), 6.87 (d, *J* = 10.4 Hz, 1H), 8.83 (s, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 22.7, 30.1, 31.8, 34.4, 35.8, 120.6, 121.6, 134.7, 138.0, 144.6, 146.8, 150.7, 166.8, 178.2, 180.4. HRMS (EI): calcd for C~15~H~13~N~3~O~2~ (M^+^), 267.1008; found, 267.1009.

### 3-Phenyl-1,2,3,4-tetrahydrobenzo\[4,5\]imidazo\[1,2-*a*\]quinazoline-8,11-dione (**4c**) {#sec4.4.3}

*R*~f~ = 0.42. Brown solid (25 mg, 76%). mp 237--239 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.08--2.16 (m, 1H), 2.28--2.32 (m, 1H), 2.96--3.02 (m, 1H), 3.06--3.13 (m, 1H), 3.14--3.20 (m, 2H), 3.27--3.32 (m, 1H), 6.80 (d, *J* = 10.3 Hz, 1H), 6.89 (d, *J* = 10.3 Hz, 1H), 7.26--7.27 (m, 1H), 7.29--7.31 (m, 2H), 7.35--7.38 (m, 2H), 8.95 (s, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 29.1, 33.1, 33.6, 38.1, 118.7, 119.8, 126.12, 126.14, 128.1, 133.1, 136.2, 142.8, 144.3, 145.0, 148.8, 164.3, 179.4, 181.5. HRMS (EI): calcd for C~20~H~15~N~3~O~2~ (M^+^), 329.1164; found, 329.1162.

### 2,3,4,5-Tetrahydro-1*H*-benzo\[4,5\]imidazo\[1,2-*a*\]cyclohepta\[*e*\]pyrimidine-9,12-dione (**4d**) {#sec4.4.4}

*R*~f~ = 0.58. Brown solid (19 mg, 71%). mp 190--192 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 1.81--1.85 (m, 2H), 1.97--2.04 (m, 4H), 2.94--2.96 (m, 2H), 3.64--3.66 (m, 2H), 6.72 (d, *J* = 8.6 Hz, 1H), 6.92 (d, *J* = 8.6 Hz, 1H), 8.54 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 25.1, 27.4, 30.7, 32.0, 34.0, 120.2, 123.2, 132.3, 135.8, 136.8, 143.4, 148.7, 166.3, 175.8, 181.6. HRMS (EI): calcd for C~15~H~13~N~3~O~2~ (M^+^), 267.1008; found, 267.1006.

### 1,2,3,4,5,6-Hexahydrobenzo\[4,5\]imidazo\[1,2-*a*\]cycloocta\[*e*\]pyrimidine-10,13-dione (**4e**) {#sec4.4.5}

*R*~f~ = 0.56. Brown solid (23 mg, 81%). mp 194--196 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.25--1.29 (m, 2H), 1.41--1.45 (m, 2H), 1.70--1.74 (m, 2H), 1.76--1.81 (m, 2H), 2.92--2.94 (m, 2H), 3.74--3.76 (m, 2H), 6.85 (d, *J* = 10.3 Hz, 1H), 6.89 (d, *J* = 10.3 Hz, 1H), 8.75 (s, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 25.0, 25.6, 28.0, 28.6, 29.2, 31.4, 123.2, 126.1, 133.9, 140.4, 146.6, 151.3, 151.9, 157.4, 174.3, 182.2. HRMS (EI): calcd for C~16~H~15~N~3~O~2~ (M^+^), 281.1164; found, 281.1167.

### 1,2,3,4,5,6,7,8,9,10-Decahydrobenzo\[4,5\]imidazo\[1,2-*a*\]cyclododeca\[*e*\]pyrimidine-14,17-dione (**4f**) {#sec4.4.6}

*R*~f~ = 0.54. Brown solid (29 mg, 85%). mp 198--200 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.41--149 (m, 8H), 1.53--1.63 (m, 4H), 1.66--1.71 (m, 2H), 1.80--1.86 (m, 2H), 2.82--2.85 (m, 2H), 3.67--3.70 (m, 2H), 6.85 (d, *J* = 10.3 Hz, 1H), 6.91 (d, *J* = 10.3 Hz, 1H), 8.83 (s, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 21.6, 21.9, 24.8, 25.1, 25.3, 25.6, 25.7, 26.0, 27.1, 28.7, 123.6, 125.5, 134.0, 140.3, 146.7, 151.1, 151.6, 158.4, 174.5, 182.1. HRMS (EI): calcd for C~20~H~23~N~3~O~2~ (M^+^), 337.1790; found, 337.1789.

### Benzo\[*f*\]benzo\[4,5\]imidazo\[1,2-*a*\]quinazoline-8,11-dione (**4g**) {#sec4.4.7}

*R*~f~ = 0.42. Brown solid (24 mg, 81%). mp 223--225 °C. ^1^H NMR (500 MHz, CDCl~3~): δ 6.81 (d, *J* = 10.3 Hz, 1H), 6.88 (d, *J* = 10.3 Hz, 1H), 7.70--7.73 (m, 1H), 7.81--7.84 (m, 1H), 8.03 (d, *J* = 8.0 Hz, 1H), 8.34 (d, *J* = 9.4 Hz, 1H), 8.72 (d, *J* = 8.4 Hz, 1H), 9.75 (d, *J* = 9.4 Hz, 1H), 10.07 (s, 1H). ^13^C NMR (125 MHz, CDCl~3~): δ 115.8, 118.7, 122.1, 125.7, 128.4, 128.9, 129.6, 130.0, 131.6, 134.9, 136.5, 137.2, 139.7, 146.5, 151.2, 153.9, 175.5, 181.5. HRMS (EI): calcd for C~18~H~9~N~3~O~2~ (M^+^), 299.0695; found, 299.0695.

### 4-Phenylbenzo\[4,5\]imidazo\[1,2-*a*\]pyrimidine-6,9-dione (**4h**) {#sec4.4.8}

*R*~f~ = 0.50. Brown solid (23 mg, 83%). mp 108--110 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 6.69 (d, *J* = 10.4 Hz, 1H), 6.81 (d, *J* = 10.4 Hz, 1H), 7.44 (d, *J* = 4.5 Hz, 1H), 7.48--7.53 (m, 2H), 7.55--7.58 (m, 1H), 7.59--7.62 (m, 2H), 8.96 (d, *J* = 4.5 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 114.5, 123.4, 127.3, 128.1, 130.5, 133.8, 134.5, 139.1, 146.0, 149.8, 152.2, 155.6, 173.6, 182.3. HRMS (EI): calcd for C~16~H~9~N~3~O~2~ (M^+^), 275.0695; found, 275.0693.

### 3-Methyl-4-phenylbenzo\[4,5\]imidazo\[1,2-*a*\]pyrimidine-6,9-dione (**4i**) {#sec4.4.9}

*R*~f~ = 0.44. Brown solid (21 mg, 72%). mp 211--212 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 2.17 (s, 3H), 6.56 (d, *J* = 10.4 Hz, 1H), 6.75 (d, *J* = 10.4 Hz, 1H), 7.47--7.55 (m, 5H), 8.92 (s, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 15.5, 121.4, 122.9, 128.2, 128.4, 129.8, 132.7, 134.3, 139.2, 145.7, 146.7, 151.3, 158.4, 173.2, 182.2. HRMS (EI): calcd for C~17~H~11~N~3~O~2~ (M^+^), 289.0851; found, 289.0849.

### 3-Butyl-4-phenylbenzo\[4,5\]imidazo\[1,2-*a*\]pyrimidine-6,9-dione (**4j**) {#sec4.4.10}

*R*~f~ = 0.55. Brown solid (26 mg, 78%). mp 188--191 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 0.71 (t, *J* = 7.4 Hz, 3H), 0.81--0.89 (m, 2H), 1.12--1.19 (m, 2H), 1.38--1.44 (m, 2H), 6.56 (d, *J* = 10.4 Hz, 1H), 6.75 (d, *J* = 10.4 Hz, 1H), 7.47--7.57 (m, 5H), 8.95 (s, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 13.4, 21.6, 28.0, 32.1, 123.1, 125.6, 128.1, 128.6, 129.8, 132.3, 134.2, 139.2, 145.7, 146.7, 151.1, 158.2, 173.2, 182.2. HRMS (EI): calcd for C~20~H~17~N~3~O~2~ (M^+^), 331.1321; found, 331.1324.

### 3-Isopropyl-4-phenylbenzo\[4,5\]imidazo\[1,2-*a*\]pyrimidine-6,9-dione (**4k**) {#sec4.4.11}

*R*~f~ = 0.44. Brown solid (24 mg, 75%). mp 194--197 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.21 (d, *J* = 7.0 Hz, 6H), 2.73--2.81 (m, 1H), 6.54 (d, *J* = 10.3 Hz, 1H), 6.75 (d, *J* = 10.3 Hz, 1H), 7.46--7.53 (m, 5H), 9.11 (s, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 22.1, 26.9, 122.6, 127.6, 128.2, 129.3, 130.1, 131.7, 133.7, 138.7, 145.3, 145.4, 150.3, 155.4, 172.6, 181.6. HRMS (EI): calcd for C~19~H~15~N~3~O~2~ (M^+^), 317.1164; found, 317.1166.

### 3,4-Diphenylbenzo\[4,5\]imidazo\[1,2-*a*\]pyrimidine-6,9-dione (**4l**) {#sec4.4.12}

*R*~f~ = 0.51. Brown solid (25 mg, 72%). mp 222--223 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 6.91 (d, *J* = 10.5 Hz, 1H), 6.96 (d, *J* = 10.5 Hz, 1H), 7.30--7.32 (m, 2H), 7.34--7.37 (m, 2H), 7.40--7.44 (m, 6H), 9.18 (s, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 121.3, 126.4, 128.1, 128.4, 128.8, 129.59, 129.61, 129.9, 134.8, 135.0, 136.8, 137.2, 137.4, 144.7, 149.2, 162.8, 176.7, 181.9. HRMS (EI): calcd for C~22~H~13~N~3~O~2~ (M^+^), 351.1008; found, 351.1010.

### 4-Ethyl-3-methylbenzo\[4,5\]imidazo\[1,2-*a*\]pyrimidine-6,9-dione (**4m**) {#sec4.4.13}

*R*~f~ = 0.47. Brown solid (18 mg, 74%). mp 173--175 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 1.27 (t, *J* = 7.3 Hz, 3H), 2.36 (d, *J* = 1.0 Hz, 3H), 2.90 (q, *J* = 7.3 Hz, 2H), 6.77 (d, *J* = 10.4 Hz, 1H), 6.83 (d, *J* = 10.4 Hz, 1H), 9.02 (q, *J* = 1.0 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 10.3, 15.0, 28.5, 120.8, 122.8, 132.2, 136.3, 137.3, 143.4, 149.5, 170.1, 176.4, 182.00. HRMS (EI): calcd for C~13~H~11~N~3~O~2~ (M^+^), 241.0851; found, 241.0852.

### 4-(Naphthalen-2-yl)benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidine-6,9-dione (**4n**) {#sec4.4.14}

*R*~f~ = 0.51. Brown solid (25 mg, 76%). mp 184--187 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 6.89 (d, *J* = 10.4 Hz, 1H), 6.95 (d, *J* = 10.4 Hz, 1H), 7.64--7.69 (m, 3H), 8.14--8.18 (m, 2H), 8.30 (d, *J* = 7.2 Hz, 1H), 8.43--8.45 (m, 1H), 8.96 (s, 1H), 9.46 (d, *J* = 7.2 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 110.3, 116.7, 123.7, 126.8, 127.5, 128.0, 128.4, 128.7, 129.0, 132.6, 132.9, 134.3, 136.1, 136.4, 137.2, 144.6, 150.2, 160.9, 176.6, 181.9. HRMS (EI): calcd for C~20~H~11~N~3~O~2~ (M^+^), 325.0851; found, 325.0850.

### 4-(Furan-3-yl)benzo\[4,5\]imidazo\[1,2-*a*\]pyrimidine-6,9-dione (**4o**) {#sec4.4.15}

*R*~f~ = 0.45. Brown solid (19 mg, 72%). mp 157--158 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 6.84 (dd, *J* = 3.6 and 1.8 Hz, 1H), 6.86 (d, *J* = 10.5 Hz, 1H), 6.91 (d, *J* = 10.5 Hz, 1H), 7.65 (dd, *J* = 3.6 and 0.6 Hz, 1H), 7.82 (d, *J* = 7.2 Hz, 1H), 8.11--8.114 (m, 1H), 9.36 (d, *J* = 7.2 Hz, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 109.0, 113.6, 115.5, 121.8, 136.5, 136.54, 137.4, 144.6, 147.7, 150.1, 150.6, 152.0, 176.6, 182.0. HRMS (EI): calcd for C~14~H~7~N~3~O~3~ (M^+^), 265.0487; found, 265.0485.

### Benzo\[4,5\]imidazo\[1,2-*a*\]quinazoline-8,11-dione (**4p**) {#sec4.4.16}

*R*~f~ = 0.40. Brown solid (20 mg, 82%). mp 253--255 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 6.91 (d, *J* = 10.3 Hz, 1H), 7.00 (d, *J* = 10.3 Hz, 1H), 7.84--7.87 (m, 1H), 8.13--8.15 (m, 1H), 8.34--8.36 (m, 1H), 9.49 (s, 1H), 9.60--9.62 (m, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 119.5, 120.0, 126.5, 127.9, 130.0, 134.5, 135.8, 139.3, 144.3, 150.0, 159.7, 175.8, 181.7. HRMS (EI): calcd for C~14~H~7~N~3~O~2~ (M^+^), 249.0538; found, 249.0535.

### 3-Fluorobenzo\[4,5\]imidazo\[1,2-*a*\]quinazoline-8,11-dione (**4q**) {#sec4.4.17}

*R*~f~ = 0.54. Brown solid (20 mg, 74%). mp 254--257 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 6.94 (d, *J* = 10.3 Hz, 1H), 7.04 (d, *J* = 10.3 Hz, 1H), 7.90--7.93 (m, 2H), 9.48 (s, 1H), 9.73--9.76 (m, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 112.1 (d, ^2^*J*~C--F~ = 22.0 Hz, 1C), 118.2 (d, ^3^*J*~C--F~ = 7.5 Hz, 1C), 120.1 (d, ^2^*J*~C--F~ = 23.3 Hz, 1C), 121.0 (d, ^3^*J*~C--F~ = 7.3 Hz, 1C), 126.7, 132.9, 134.9, 139.2, 145.2, 148.0, 155.4 (d, ^4^*J*~C--F~ = 3.0 Hz, 1C), 157.3 (d, ^1^*J*~C--F~ = 246.0 Hz, 1C), 174.8, 181.8. HRMS (EI): calcd for C~14~H~6~FN~3~O~2~ (M^+^), 267.0444; found, 267.0447.

### Benzo\[*h*\]benzo\[4,5\]imidazo\[1,2-*a*\]quinazoline-10,13-dione (**4r**) {#sec4.4.18}

*R*~f~ = 0.43. Brown solid (21 mg, 71%). mp 251--253 °C. ^1^H NMR (500 MHz, DMSO-*d*~6~): δ 6.92 (d, *J* = 10.3 Hz, 1H), 7.01 (d, *J* = 10.3 Hz, 1H), 7.68--7.72 (m, 1H), 7.91--7.94 (m, 1H), 8.17 (d, *J* = 8.4 Hz, 1H), 8.27 (d, *J* = 8.0 Hz, 1H), 8.34 (d, *J* = 8.5 Hz, 1H), 9.66 (s, 1H). ^13^C NMR (125 MHz, DMSO-*d*~6~): δ 119.3, 122.2, 123.4, 125.9, 126.3, 127.8, 127.9, 128.8, 130.4, 134.5, 134.8, 139.5, 145.4, 151.5, 158.0, 159.5, 175.0, 182.4. HRMS (EI): calcd for C~18~H~9~N~3~O~2~ (M^+^), 299.0695; found, 299.0692.
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